VERAXA Biotech AG (NASDAQ: VRXA) announced on July 20 that it has received Scientific Advice from Germany’s Paul-Ehrlich-Institute (PEI), providing regulatory feedback that supports the company’s proposed development strategy for its lead BiTAC-TCE program. The PEI’s guidance addresses the biological rationale, safety assessments, and non-clinical development plan for VERAXA’s novel therapeutic platform, which the company believes reduces development uncertainty as it advances toward clinical studies (https://ibn.fm/zBiDU).
The BiTAC-TCE platform is designed to harness bispecific T-cell engagers to direct the immune system against cancer cells. VERAXA’s lead candidate previously demonstrated encouraging preclinical data, presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The company continues to build a diversified oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates (ADCs), and other engineered antibody formats.
Scientific Advice procedures allow drug developers to consult with regulatory experts before clinical trials begin, helping companies align their development strategies with regulatory expectations regarding safety, tolerability, and efficacy. The PEI’s support provides early clarity on the biological rationale and non-clinical development plan, potentially streamlining the path to first-in-human studies.
The regulatory milestone follows continued progress in manufacturing and development as VERAXA advances next-generation antibody therapeutics for cancer. The company’s proprietary BiTAC-TCE platform represents a novel approach to engaging T cells in tumor destruction, and the positive PEI feedback could accelerate the timeline for clinical entry.
VERAXA Biotech is an emerging leader in designing novel cancer therapies, with a focus on engineered antibodies. The company’s most advanced BiTAC-TCE candidate is expected to move toward clinical development following this regulatory guidance. The PEI’s Scientific Advice is a key step in de-risking the program and aligning with regulatory standards before initiating human trials.
For more information on VERAXA Biotech and its pipeline, visit the company’s newsroom at https://ibn.fm/VRXA.
